Retina

ARCATUS, also known as XIPERE®, utilises a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition

G6501 is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

The company announced preliminary US net revenues of about $74 million for the injection, approved by the FDA earlier this year.

Robyn Guymer, MBBS, PhD, Deputy Director, Centre for Eye Research Australia, and Professor of Surgery (Ophthalmology), University of Melbourne, Australia, discussed the study findings at the 23rd annual EURETINA Congress in Amsterdam, the Netherlands

This milestone was announced by Clearside Biomedical, Inc., Arctic Vision's partner. ARCATUS, also known as XIPERE®, utilizes a revolutionary suprachoroidal delivery platform, offering new hope to patients in China suffering from this vision-threatening condition.

The new range of pure and premixed gases are intended for medium-term use in retinal surgery.

We spoke with Michael Singer, MD who provided an overview of his presentation, "MCO-010 Optogenetic Therapy to Treat Stargardt Disease: Safety and Efficacy through Week 48 in the Phase 2a STARLIGHT Clinical Trial"

Dr Ali Erginay of Lariboisière Hospital in Paris, France, discusses his EURETINA presentation, "Introducing optomap® Ultra-widefield Colour Red-Green-Blue Multimodal Imaging"

The collaboration will drive an effort to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases.

Our team spoke to David Almeida, MD, PhD, MBA about his EURETINA presentation titled, The Real-World Efficacy and Safety of Faricimab in Neovascular AMD: The TRUCKEE Study.

Our team spoke to Varun Chaudhary, MD, about his EURETINA presentation, titled "Systematic Review and Metanalysis in Macular Hole RCTs – Posturing after Macular Hole Surgery."

Our team spoke to Varun Chaudhary, MD, about his EURETINA presentation, titled "Systematic Review and Metanalysis in Macular Hole RCTs – Posturing after Macular Hole Surgery"

Altris also has advanced AI models to enable vendor-neutral retina layers segmentation as well as detection and visualization of more than 70 retina conditions such as dry and wet age-related macular degeneration, geographic atrophy, diabetic retinopathy, diabetic macular edema and central retinal vein occlusion.

In this EyePod® episode, David Hutton sits down with Shankar Musunuri, CEO of Ocugen to discuss updated data for OCU400.

The specialty pharmaceutical research company’s new retinal vascular dysfunction model can have an impact on the research and development of new drugs for retinal vascular diseases.

Dr Barbara Parolini gives her guidance on navigating and managing the pathology in stages

Attendees can take advantage of many satellite symposia, sponsored by industry and feauring experts from around the world

Experts in all aspects of retinal care will gather at the RAI Amsterdam Convention Centre, located in the Zuidas business district of the city, which is a short distance from historic Amsterdam with is canals, museums, and shops

According to the companies, the partnership will roll out a proprietary system that has earned FDA breakthrough designation, one of the few ophthalmic devices to achieve this status in almost a decade.

According to a news release, the J-code for SYFOVRE will become effective on October 1, 2023.

To educate patients on the disease, the company has enlisted the help of actor Eric Stonestreet and his mother, Jamey.

Kiora CEO Brian Strem, PhD, offers an update on the development of KIO-301, a molecule that selectively targets retinal ganglion cells, giving them the ability to sense light.

The research will focus on the compound's impact on biomolecular condensates, which are implicated as a key driver of pathology in neurodegeneration and diseases impacting high metabolic organs. Because the retina is one of the highest energy consuming systems in the human body, deficits in energy supply can be catastrophic.

Researchers from the University of Barcelona are looking to unlock the function of genes in order to design therapies to treat patients diagnosed with retinitis pigmentosa.

VR will have very useful applications in many fields. One of those fields is ophthalmology.